☰

Shoghag B. Panjarian, Ph.D. - Publications

Affiliations: 
2012 Medicine University of Pittsburgh, Pittsburgh, PA, United States 
Area:
Pharmacology
Tree Info Similar researchers PubMed Report error

16 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Panjarian S, Madzo J, Slater C, Jelinek J, Chen X, Issa J. Abstract P3-05-03: Identification of epigenetically silenced breast cancer driver genes Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P3-05-03  0.302
2018 Good CR, Panjarian S, Kelly AD, Madzo J, Patel B, Jelinek J, Issa JJ. TET1-mediated hypomethylation activates oncogenic signaling in triple-negative breast cancer. Cancer Research. PMID 29891505 DOI: 10.1158/0008-5472.Can-17-2082  0.359
2016 Sato T, Cesaroni M, Chung W, Panjarian S, Tran A, Madzo J, Okamoto Y, Zhang H, Chen X, Jelinek J, Issa JJ. Transcriptional Selectivity of Epigenetic Therapy in Cancer. Cancer Research. PMID 27879268 DOI: 10.1158/0008-5472.Can-16-0834  0.348
2016 Badger J, Grover P, Panjarian SB, Engen JR, Smithgall TE, Makowski L. The c-Abl Tyrosine Kinase Adopts Multiple Active Conformational States in Solution. Biochemistry. PMID 27166638 DOI: 10.1021/Acs.Biochem.6B00202  0.706
2016 Sato T, Cesaroni M, Tran A, Madzo J, Okamoto Y, Zhang H, Panjarian S, Jelinek J, Issa J. Abstract B42: Decitabine specifically targets genes that gain DNA methylation and lose expression in cancer and can be combined with histone methylation inhibitors for increased efficacy Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-B42  0.34
2016 Sato T, Cesaroni M, Panjarian S, Tran A, Madzo J, Okamoto Y, Zhang H, Chen X, Jelinek J, Issa JJ. Abstract 2657: Target specificity of epigenetic therapy in cancer Cancer Research. 76: 2657-2657. DOI: 10.1158/1538-7445.Am2016-2657  0.335
2013 Panjarian S, Iacob RE, Chen S, Engen JR, Smithgall TE. Structure and dynamic regulation of Abl kinases. The Journal of Biological Chemistry. 288: 5443-50. PMID 23316053 DOI: 10.1074/Jbc.R112.438382  0.675
2013 Panjarian S, Iacob RE, Chen S, Wales TE, Engen JR, Smithgall TE. Enhanced SH3/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors. The Journal of Biological Chemistry. 288: 6116-29. PMID 23303187 DOI: 10.1074/Jbc.M112.431312  0.713
2013 Panjarian SB, Iacob R, Shugui C, Wales T, Engen JR, Smithgall TE. Abstract 2221: Enhanced SH3:linker interaction allosterically sensitizes Abl kinases to small molecule inhibitors. Cancer Research. 73: 2221-2221. DOI: 10.1158/1538-7445.Am2013-2221  0.723
2012 Panjarian SB, Chen S, Iacob R, Wales T, Engen JR, Smithgall TE. Abstract 5599: Allosteric regulation of Abl and Bcr-Abl kinases by enhanced SH3:linker interaction Cancer Research. 72: 5599-5599. DOI: 10.1158/1538-7445.Am2012-5599  0.734
2011 Panjarian SB, Chen S, Iacob R, Wales TE, Engen JR, Smithgall TE. Abstract B75: Allosteric regulation of Abl and Bcr-Abl kinases by enhanced SH3:linker interaction. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B75  0.738
2010 Panjarian S, Chen S, Engen J, Smithgall T. Enhanced SH3:Linker Interaction Suppresses Activating Mutations of the c-Abl Protein-Tyrosine Kinase. Blood. 116: 1208-1208. DOI: 10.1182/Blood.V116.21.1208.1208  0.712
2010 Panjarian S, Smithgall TE. Abstract 632: Cross-resistance of myeloid cells transformed with Bcr-Abl imatinib-resistant mutant T315I to Src-family kinase inhibitors Cancer Research. 70: 632-632. DOI: 10.1158/1538-7445.Am10-632  0.612
2009 Choi Y, Seeliger MA, Panjarian SB, Kim H, Deng X, Sim T, Couch B, Koleske AJ, Smithgall TE, Gray NS. N-myristoylated c-Abl tyrosine kinase localizes to the endoplasmic reticulum upon binding to an allosteric inhibitor. The Journal of Biological Chemistry. 284: 29005-14. PMID 19679652 DOI: 10.1074/Jbc.M109.026633  0.694
2008 Panjarian S, Kozhaya L, Arayssi S, Yehia M, Bielawski J, Bielawska A, Usta J, Hannun YA, Obeid LM, Dbaibo GS. De novo N-palmitoylsphingosine synthesis is the major biochemical mechanism of ceramide accumulation following p53 up-regulation. Prostaglandins & Other Lipid Mediators. 86: 41-8. PMID 18400537 DOI: 10.1016/J.Prostaglandins.2008.02.004  0.355
2003 El-Assaad W, Kozhaya L, Araysi S, Panjarian S, Bitar FF, Baz E, El-Sabban ME, Dbaibo GS. Ceramide and glutathione define two independently regulated pathways of cell death initiated by p53 in Molt-4 leukaemia cells. Biochemical Journal. 376: 725-732. PMID 12967322 DOI: 10.1042/Bj20030888  0.31
Show low-probability matches.